Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrimethamine + sulfadiazine
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pyrimethamine + sulfadiazine is a combination antimicrobial therapy that works synergistically to treat parasitic infections, particularly toxoplasmosis. Pyrimethamine inhibits dihydrofolate reductase while sulfadiazine competes with p-aminobenzoic acid, both disrupting folate metabolism in parasites and preventing their DNA synthesis and reproduction. This combination is particularly effective against Toxoplasma gondii infections and is typically administered with folinic acid to reduce side effects.
02
Targets
DHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)DHPS (Dihydropteroate synthase)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on pyrimethamine + sulfadiazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrimethamine + sulfadiazine.